Responsible for setting gene therapy strategy across Astellas, including long-term vision, business development plans and key capabilities required for execution. Provide strategic direction to Astellas Gene Therapies (AGT) organization (spanning research, manufacturing, development and commercial)Chair the Primary Focus Leadership team with accountability for gene therapy portfolio and operating budgetLead for BD strategy for Astellas gene therapy portfolioKey external media contact for gene therapy business

Led Gene Therapy Program Management function with responsibility for development of portfolio of AAV-delivered genetic medicines, redesigned Core Team and Extended Team model, from candidate nomination to launch alongside revamp of internal governance for decision-making on programs across Astellas Gene Therapies (AGT) divisions and their interfaces with Astellas Line responsibility for all Global Development Project Leaders and Global Project Management Leaders in AGT, Gene Therapy Portfolio Strategy function and local leadership for IT, HR and financeServed as key cross-divisional, cross-functional member of the AGT Center of Excellence Leadership Team Coordinated corporate-level planning and reporting including creation of objectives, performance tracking and quarterly review meetings with Astellas executive committee (EC)Set up and co-chaired AGT Implementation Office, accountable to Astellas EC, driving integration strategy and execution across the legacy Audentes business, including shared service structures for G&A functions

Team lead for multiple products responsible for generating revenue of $500M+Led BLA and MAA approval for PALYNZIQ® followed by successful sBLA filing for 60mg strength product expanding treatable patient population. Cross-portfolio core team lead for BioMarin’s phenylketonuria (PKU) franchise including KUVAN® and BMN-307 gene therapy, opening the BMN-307 IND in late 2019.Core team lead for ALDURAZYME® partnered with Sanofi-Genzyme

Commercialization Strategy and Market Analytics for COPD and Asthma markets, supported global launch of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® with GSK• Grew market share of RELVAR®/BREO® ELLIPTA® from 2% to 18% and ANORO® ELLIPTA® from 1.5% to 15% with GSK between Jan ‘15 and Mar ‘18 :o Created strategies to overcome barriers to uptake, built from payer and physician-level market researcho Integrated real-time prescription trends, payer coverage, and promotional spend metrics to generate hypotheses and steer market research in the US and EU respiratory marketso Standing member of GSK/Innoviva governance committeesBusiness Developmento Evaluated over 33 commercial and late-stage products for investment including biologics, small molecules and medical devices targeting oncology, pain, metabolic, cardiovascular and anti-infective disease areas in both US and worldwide markets

Delivered 5 projects into Phase 1 or Phase 2 clinical trials:o Identified a novel COPD patient segment and redesigned the development and formulation plan for TD-4208, managing the project from preclinical to Phase 2 proof-of-concept. (later launched as YUPELRI® with Mylan/Viatris).o Successfully initiated Phase 1 for HCV product candidate following early FDA engagement to address unusual preclinical safety findings o Supported anti-bacterial product development through early Phase 2, resolving key product therapeutic index challengeLed a new portfolio-wide quarterly project reporting process for senior leadershipCreated and led new project management role for large multi-project GSK respiratory alliance (Phase 2 through NDA approval) and cardiovascular research collaboration with Merck (preclinical)

(Scientist, 2000; Research Scientist 2002; Senior Scientist 2005; Associate Director 2008)Established track record as Project Team Leader with three early stage projects in rheumatology and anti-infective areas:o Led new team that identified novel inhibitors of Xanthine Oxidase for gout in 12months from project initiationo Achieved team turnaround of antibacterial program leading to a new lead series of potent and selective inhibitors of LpxC for P. Aeruginosa and K. Pneumoniae within 12 monthsCMC Lead for inhaled dual-acting muscarinic antagonist/beta-2 agonist program and overactive bladder program transitioning two lead candidates from research into Phase 2o Achieved GSK opt-in for a further two Phase 1/2-ready candidates in COPD after developing a novel solid form/early scaleup screening program for dry powder inhaler compatibilityo Represented CMC function during diligence meetings with potential partnersStarted the first external research chemistry capability for Theravance in China, managing ~20 member FTE teams in Beijing and Shanghai

Joined newly formed research team, setting up high throughput chemistry capability for BioChem Pharma • Introduced high throughput chemistry techniques to Hepatitis and HIV projects, and to Opioid Pain project (with AstraZeneca)• Managed solid phase synthesis project with University of Alberta and $2M screening library collaboration with Evotec (UK)

Medicinal and Combinatorial Chemist supporting cardiovascular, respiratory and antiviral research projects.